Abstract
At our center, relapsed mantle cell lymphoma (MCL) can be treated with maintenance therapy composed of consecutive low-dose lenalidomide and short-term, high-dose dexamethasone (LD regimen), which achieves good responses (longer overall survival and progression-free survival) and low toxicity. Cereblon is probably targeted by both lenalidomide and dexamethasone, which leads to synergistic cytotoxicity in MCL by inhibiting the interleukin-6/signal transducer and activator of transcription 3 (IL-6/STAT3), phosphatidylinositol 3-kinase (PI3K)/AKT and AKT2/Forkhead box O3 (FOXO3A)/BCL2-like 11 (BIM) pathways. The two drugs synergistically inhibit the same pathways, but through different sites. Cereblon was found expressed in most of the MCL tissues (91.3% positivity). Moreover, cereblon expression is positively correlated with LD regimen sensitivity: long-term lenalidomide exposure downregulates cereblon and induces multi-drug resistance against lenalidomide, dexamethasone, cytarabine, cisplatin, and methotrexate in vitro. Removal of lenalidomide resensitizes lenalidomide-resistant MCL cells to lenalidomide and dexamethasone. Our work suggests that rotating the LD regimen with other regimens would improve MCL maintenance therapy.
References
Oct 24, 2007·The Journal of Allergy and Clinical Immunology·Raif S GehaUNKNOWN International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee
Jul 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter H WiernikThomas M Habermann
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lei WuJ Blake Bartlett
Feb 28, 2009·British Journal of Haematology·Thomas M HabermannJoseph M Tuscano
May 26, 2009·Biomedical and Environmental Sciences : BES·Shao-Ling WangChang-Hao Sun
Sep 8, 2009·Haematologica·Georg AueAdrian Wiestner
Oct 14, 2010·Blood·Patricia Pérez-GalánAdrian Wiestner
Dec 21, 2010·Critical Reviews in Oncology/hematology·Andre Goy, Brad Kahl
Jan 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T E WitzigM S Czuczman
Nov 8, 2011·Haematologica·Francesco ZajaRenato Fanin
Feb 23, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pasquale Sansone, Jacqueline Bromberg
May 4, 2012·Leukemia·A Lopez-GironaR Chopra
May 23, 2012·American Journal of Hematology·Julie M Vose
Jul 5, 2012·Advances in Hematology·Marco Gunnellini, Lorenzo Falchi
Sep 13, 2012·Blood·Liang ZhangQing Yi
Sep 22, 2012·British Journal of Haematology·P McKayUNKNOWN British Committee for Standards in Haematology
Dec 13, 2012·Blood·Annemiek BroylUNKNOWN German GMMG Group
Jul 31, 2013·Cytometry. Part B, Clinical Cytometry·Karthick Raja Muthu RajaRoman Hajek
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andre GoyThomas E Witzig
Sep 14, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P L ZinzaniT E Witzig
Jun 11, 2014·Blood·Yuan Xiao ZhuA Keith Stewart
Jul 6, 2014·Leukemia & Lymphoma·Vicki A MorrisonBruce D Cheson
Sep 13, 2014·The Journal of Biological Chemistry·Marylynn SnyderJ Jillian Zhang
May 9, 2015·The Journal of Pathology·Antonino CarboneCarmelo Carlo-Stella
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John P LeonardBruce D Cheson